Ipsen News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

11.06.21	ISPRM 2021: New Ipsen Analysis Highlights Potential Treatment Gap in Adults Living With Spasticity (Businesswire)
01.06.21	Ipsen Announces the Launch of an Employee Shareholding Plan (Businesswire)
28.05.21	Ipsen Confirms U.S. FDA Accepts New Drug Application for Palovarotene as the First Potential Treatment Worldwide for Fibrodysplasia Ossificans Progressiva (FOP) (Businesswire)
11.05.21	Ipsen Opts-in to Join Exelixis With Ongoing Development of Cabometyx® for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results (Businesswire)
22.04.21	Ipsen Delivers Encouraging Sales Growth in the First Quarter of 2021 Despite the Pandemic, and Confirms Its Full-Year Guidance (Businesswire)
31.03.21	European Commission Approves Cabometyx® in Combination With Opdivo® as a First-Line Treatment for Patients Living With Advanced Renal Cell Carcinoma (Businesswire)
26.02.21	Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination With Opdivo® as First-line Treatment for Patients Living With Advanced Renal Cell Carcinoma (Businesswire)
22.02.21	Ipsen Announces New Data from the Phase II CLARINET FORTE Study Which Demonstrated Preservation of Quality of Life When Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) (Businesswire)
05.02.21	Ipsen to Showcase Commitment to Going Beyond Traditional Outcome Measures for Patients Living With Renal Cell Carcinoma at ASCO GU 2021 (Businesswire)
20.01.21	Ipsen Appoints Gwenan White as Executive Vice President, Communications and Public Affairs (Businesswire)
15.01.21	TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications (Businesswire)
01.12.20	Ipsen Highlights New Strategic Priorities and Provides Mid-Term Financial Outlook (Businesswire)
30.11.20	Ipsen Receives FDA Fast Track Designation for Investigational Irinotecan Liposome Injection (ONIVYDE®) as a Second-Line Monotherapy Treatment for Small Cell Lung Cancer (SCLC) (Businesswire)
22.10.20	Ipsen Delivers Sales Growth in the First Nine Months of 2020 Despite the Impact of COVID-19 and Confirms Its 2020 Full Year Guidance (Businesswire)
25.09.20	Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer (Businesswire)
18.09.20	ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months (Businesswire)
14.09.20	Ipsen Showcases Commitment to Patient-centric Advances in Oncology With Record Number of Abstracts to Be Presented at ESMO 2020 Virtual Congress (Businesswire)
10.09.20	Ipsen to Present New Insights at ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP), Including Global Phase III MOVE Trial Results (Businesswire)
25.08.20	Ipsen to Present Results From MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP), at ASBMR 2020 Annual Meeting (Businesswire)
02.07.20	Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer (Businesswire)
17.06.20	Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as a First-Line Combination Treatment for Metastatic Pancreatic Cancer (Businesswire)
08.06.20	Ipsen Initiates a Share Buyback Program to Cover Its Share Allocation Plan (Businesswire)
08.06.20	Ipsen Demonstrates Continued Commitment to Rare Diseases With Eight Abstracts Accepted at ENDO 2020 Published in the Journal of the Endocrine Society (Businesswire)
29.05.20	Ipsen Appoints David Loew as Chief Executive Officer (Businesswire)
23.05.20	Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence (Businesswire)
19.05.20	Ipsen Announces Publication of First Matching-Adjusted Indirect Comparison of Cabometyx® (cabozantinib) Versus regorafenib in Advanced Hepatocellular Carcinoma in Advances in Therapy (Businesswire)
04.05.20	Ipsen enters into an option agreement with IRICoR and Université de Montréal for a discovery-stage oncology program (Businesswire)
22.04.20	Ipsen Reports Solid Sales Growth in First Quarter 2020 With Limited COVID-19 Impact (Businesswire)
01.04.20	Ipsen Donates €2 Million to the Institut Pasteur to Support Research on COVID-19 (Businesswire)
26.03.20	Ipsen Provides Update on Palovarotene Clinical Programs (Businesswire)
25.03.20	Ipsen Provides COVID-19 Update (Businesswire)
11.03.20	Ipsen Data Presented during ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs and Acromegaly (Businesswire)
24.01.20	Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria (Businesswire)
14.01.20	Ipsen Appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer (Businesswire)
06.01.20	Ipsen: Dysport® (clostridium botulinum type A toxin-haemagglutinin complex) now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsy (Businesswire)
18.12.19	Ipsen Announces Departure of David Meek as Chief Executive Officer (Businesswire)
06.12.19	Ipsen Initiates Partial Clinical Hold for Palovarotene IND120181 and IND135403 Studies (Businesswire)
05.11.19	Ipsen Appoints Howard Mayer, M.D. as Executive Vice President and Head of Research and Development (Businesswire)
05.11.19	Proposed reclassification of Ipsen shares held by Mayroy (Businesswire)
31.10.19	Ipsen presents new analyses utilizing modern data mining approaches at ISPOR Europe 2019 (Businesswire)
24.10.19	Ipsen Delivers Strong Double-digit Sales Growth for the Third Quarter of 2019 and Confirms Full Year 2019 Guidance (Businesswire)
16.10.19	Ipsen and Blueprint Medicines Announce Exclusive Global License Agreement to Develop and Commercialize BLU-782 for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) (Businesswire)
26.09.19	Ipsen Showcases Studies at the ESMO 2019 Congress Highlighting Progress in New Approaches for Difficult-to-Treat Cancers (Businesswire)
20.09.19	Ipsen to Present New Data at 13th Annual Conference of the International Liver Cancer Association (ILCA 2019) (Businesswire)
12.06.19	Debiopharm and Ipsen Extend Their Strategic Decapeptyl® (triptorelin) Partnership for Another 15 Years (Businesswire)
30.05.19	KNDL 2019-KNSQ Mortgage Trust -- Moody's assigns definitive ratings to Five CMBS classes of KNDL 2019-KNSQ Mortgage Trust (Moodys)
24.05.19	New Investigational Clinical Data for Ipsen’s Oncology Products in 11 Solid Tumor Types to Be Presented at 2019 ASCO Annual Meeting (Businesswire)
14.05.19	Ipsen to Host an Investor Day to Highlight Its Innovative R&D Pipeline and Provide Financial Outlook for 2022 (Businesswire)
08.05.19	KNDL 2019-KNSQ Mortgage Trust -- Moody's assigns provisional ratings to five CMBS classes of KNDL 2019-KNSQ Mortgage Trust (Moodys)
08.05.19	Moody's assigns provisional ratings to five CMBS classes of KNDL 2019-KNSQ Mortgage Trust (Moodys)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	537.20	1.17 %	K V
Part Grp Hldg	1’255.50	0.36 %	K V
Roche Hldg G	252.30	0.36 %	K V
Novartis	92.19	0.28 %	K V
Alcon	77.80	0.23 %	K V
ABB	49.23	-0.63 %	K V
CieFinRichemont	121.55	-0.65 %	K V
UBS Group	27.51	-0.90 %	K V
Sika	226.10	-1.09 %	K V
Logitech Intl	70.48	-2.08 %	K V